GSA Capital Partners LLP Invests $1.01 Million in Aldeyra Therapeutics, Inc. $ALDX

GSA Capital Partners LLP purchased a new position in shares of Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) during the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 472,564 shares of the biotechnology company’s stock, valued at approximately $1,007,000.

Several other large investors also recently modified their holdings of ALDX. Global Retirement Partners LLC bought a new position in Aldeyra Therapeutics in the 4th quarter valued at about $52,000. CIBC Private Wealth Group LLC bought a new stake in shares of Aldeyra Therapeutics during the 3rd quarter valued at $55,000. BNP Paribas Financial Markets lifted its position in Aldeyra Therapeutics by 36.9% during the third quarter. BNP Paribas Financial Markets now owns 10,610 shares of the biotechnology company’s stock worth $55,000 after purchasing an additional 2,859 shares during the period. Federation des caisses Desjardins du Quebec boosted its position in shares of Aldeyra Therapeutics by 25.8% during the 4th quarter. Federation des caisses Desjardins du Quebec now owns 12,187 shares of the biotechnology company’s stock worth $63,000 after acquiring an additional 2,500 shares in the last quarter. Finally, Caption Management LLC boosted its holdings in shares of Aldeyra Therapeutics by 110.6% in the 2nd quarter. Caption Management LLC now owns 12,664 shares of the biotechnology company’s stock valued at $49,000 after purchasing an additional 132,358 shares in the last quarter. 59.71% of the stock is owned by institutional investors.

Insider Transactions at Aldeyra Therapeutics

In related news, CEO Todd C. Brady acquired 250,000 shares of the firm’s stock in a transaction on Wednesday, June 3rd. The stock was purchased at an average cost of $1.67 per share, with a total value of $417,500.00. Following the acquisition, the chief executive officer owned 1,721,298 shares of the company’s stock, valued at approximately $2,874,567.66. This trade represents a 16.99% increase in their position. The purchase was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Company insiders own 11.80% of the company’s stock.

Aldeyra Therapeutics Stock Performance

Shares of NASDAQ ALDX opened at $1.56 on Tuesday. The firm’s 50-day moving average price is $1.80 and its 200-day moving average price is $2.56. The firm has a market capitalization of $94.11 million, a P/E ratio of -4.00 and a beta of 1.22. Aldeyra Therapeutics, Inc. has a 1-year low of $1.07 and a 1-year high of $6.17.

Aldeyra Therapeutics (NASDAQ:ALDX) last announced its quarterly earnings data on Thursday, August 6th. The biotechnology company reported ($0.09) EPS for the quarter, meeting analysts’ consensus estimates of ($0.09). Equities research analysts forecast that Aldeyra Therapeutics, Inc. will post -0.43 EPS for the current year.

Analysts Set New Price Targets

A number of equities research analysts have recently weighed in on ALDX shares. Weiss Ratings downgraded shares of Aldeyra Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Wednesday, May 20th. Wall Street Zen cut Aldeyra Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday. One research analyst has rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, Aldeyra Therapeutics presently has a consensus rating of “Hold” and a consensus price target of $5.50.

Aldeyra Therapeutics Company Profile

Aldeyra Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel small molecule therapies for immune-mediated diseases. The company’s research efforts center on targeted alkenals, a class of reactive aldehyde species that play a key role in inflammatory pathways. By selectively modulating these pathways, Aldeyra aims to address both ocular and systemic indications with high unmet medical need.

The company’s lead product candidate, reproxalap, is being investigated in several ophthalmic disorders, including dry eye disease, allergic conjunctivitis and non-infectious anterior uveitis.